Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 38

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 1
Chunk 38
---
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) 

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,(in millions, except per share data)2025202420252024Net sales$5,065 $4,209 $14,788 $12,186 Cost of products sold (excluding amortization expense)1,523 1,312 4,613 3,791 Gross profit3,542 2,897 10,175 8,395 Operating expenses:Selling, general and administrative expenses1,741 1,562 5,053 4,372 Research and development expenses514 407 1,483 1,156 Royalty expense12 5 40 24 Amortization expense225 205 669 631 Intangible asset impairment charges0 — 46 276 Contingent consideration net expense (benefit)11 (23)11 (4)Restructuring net charges (credits)(8)8 85 12  2,494 2,164 7,387 6,467 Operating income (loss)1,048 733 2,788 1,928 Other income (expense):Interest expense(87)(79)(259)(225)Other, net(23)14 156 (7)Income (loss) before income taxes939 669 2,685 1,697 Income tax expense (benefit)183 200 463 413 Net income (loss)755 468 2,222 1,284 Net income (loss) attributable to noncontrolling interests(0)(0)(4)(4)Net income (loss) attributable to Boston Scientific common stockholders$755 $469 $2,226 $1,288 Net income (loss) per common share — basic$0.51 $0.32 $1.50 $0.88 Net income (loss) per common share — diluted$0.51 $0.32 $1.49 $0.87 Weighted-average shares outstandingBasic1,481.7 1,472.7 1,479.6 1,470.6 Diluted1,495